论文部分内容阅读
加入WTO后,我国的医药商业企业为应对全球的医药市场竞争,逐步开始了规模化、集约化经营之路,并且通过资产重组、并购等方式,形成了一批规模化经营的医药商业企业,这在提高医药商业竞争力方面取得了一些的成绩。这种新的经营模式最根本的目的就是降低成本,提高竟争力,参与全球医药市场竞争。而事实上,目前医药商业在新一轮重整后的成本并没实实在在地降下来,还存在许多制约我国医药商业发展的因素:
After China’s accession to the WTO, the pharmaceutical commercial enterprises of our country have gradually started the way of large-scale and intensive management in order to cope with the global pharmaceutical market competition. A large number of large-scale pharmaceutical commercial enterprises have been formed through asset restructuring and mergers and acquisitions. This has made some achievements in enhancing the commercial competitiveness of the pharmaceutical industry. The most fundamental purpose of this new business model is to reduce costs, improve competitiveness and participate in the global pharmaceutical market. In fact, the current pharmaceutical business in the new round of restructuring costs have not really come down, there are still many factors that restrict the development of China’s pharmaceutical business: